info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Controlled Release Drug Delivery Market Share

ID: MRFR//5330-HCR | 90 Pages | Author: Rahul Gotadki| November 2024

The Controlled Release Drug Delivery Market which is at the world map of pharmaceutical innovations has a changing landscape where the companies use different strategies as for the market share posting. The strategies for the leading firms have been demonstrated by permanent technological upgrading. Consumer product companies commit heavily to research and development in an attempt to develop new drug delivery systems that are controlled release in nature, including of microspheres, nanoparticles, and implants. These companies exploit science based formulations that maximize the level and potency of effect, and offer sustained and targeted release of medicines to attract the attention of healthcare providers and patients seeking superior therapeutic results, optimal patient compliance, and less adverse reactions.

Pricing policies are one of the major determinants used to triangulate market share in the Controlled Release Drug Delivery market. Certain organizations choose commodity strategy by supplying their controlled release formulates at lower rates so as to attract customers from mass market segments of pharmaceutical industry and healthcare institutes. Then, premium strategy is explored by such companies that are brought into the market by underlining the better efficacy, safety, or unique features of the controlled release of the drug, targeting companies and healthcare providers who are willing to pay for high-quality and advanced drug delivery systems.

The market segmentation is the backbone of the process, and drugs are customized to the needs of specific treating areas or patient populations as the targeted release delivery systems permit. Such as structures could be meant for oncology, central nervous system illnesses, or long-running cases that would all call for bespoke approaches in drug delivery. With this niche product development approach, the companies can achieve more by positioning themselves as the experts concentrated on specific part of the Controlled Release Drug Delivery Market and meeting the demand by the pharmaceutical manufacturers and practitioners at the health facilities.

Indeed, distributional channel strategy plays a determining role for exposing controlled release drug delivery technologies on the market and making them possible to consumers. Collaboration with such entities as pharmaceutical companies, CDMOs (contract development and manufacturing organizations), and research institutions is part of the strategies of these companies in the expansion of their effectiveness. Digital platforms are now widely used by high-level licensees for technology collaboration, and educational resources, minimizing time and costs for industry stakeholders who are looking for cutting-edge drug delivery options.

Strategic linkages and synergies with pharmaceutical firms are playing a pivotal role as far as market positioning is concerned. Companies, therefore, forge strategic cooperations to advance next-generation drug formulation projects, co-promotional arrangements, and joint research projects. This is because they want to stay adequately informed about innovative technologies in controlled release drug delivery. Engaging in these collaborations further develops the scientific reputation of drug delivery systems which thereby, helps to identify and explore various innovative therapeutic approaches.

Covered Aspects:

Report Attribute/Metric Details
Growth Rate 10.60% (2023-2032)

Global Controlled Release Drug Delivery Market Overview


Controlled Release Drug Delivery Market Size was valued at USD 20.5 Billion in 2022. The Controlled Release Drug Delivery market industry is projected to grow from USD 22.67 Billion in 2023 to USD 50.67 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.60% during the forecast period (2023 - 2032).The increasing frequency of chronic illnesses, along with the growing demand for controlled release medicine delivery are the key market drivers enhancing the market growth. 


Controlled Release Drug Delivery Market Overview


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Zydus Lifesciences announced that it had introduced Mirabegron extended-release tablets of 25 mg to the U.S. market in April 2024. The company will manufacture this drug to treat overactive bladder symptoms that show urgent urinary incontinence and increased rates of micturition at a group’s formulation manufacturing facility based in Ahmedabad, India. Zydus Lifesciences also noted that it had already obtained final approval from the United States Food and Drug Administration (USFDA) for marketing Mirabegron extended-release tablets USP 25 mg and 50 mg. The firm has claimed having launched the generic version of Mirabegron extended-release tablets, USP 25 mg, among the first suppliers in the United States market and is set to launch a version with strength of 50mg soon.


IFF, a global leader in the food & beverages industry as well as home and personal care products, announces its new controlled-release platform for its range of controlled-release products like METHOCEL™, ETHOCEL™, and POLYOX™. The “Timing is Everything” brand provides full pharmaceutical solutions regarding therapies to the advantage of patients, stressing on-time delivery guidelines on medicinal ingredients while enhancing patient compliance. It has educational resources for partners, including access to experts in different fields.


Eli Lilly and Company (NYSE: LLY) announced that Omvoh™ infusion (300 mg/15 mL)/injection (100 mg/mL), the first interleukin-23p19 (IL-23p19) antagonist approved by the FDA for moderately to severely active ulcerative colitis (U.C.) treatment in adults was approved by U.S Food and Drug Administration today October 2023. Omvoh is a significant breakthrough because it is currently the only U.C. treatment specifically tailored toward IL-23 p19, a cytokine responsible for inflammation related to ulcerative colitis. The support of the approval was based on data from the LUCENT program, which included two randomized, double-blind, placebo-controlled Phase 3 clinical trials: one twelve-week induction study (UC-1) and one forty-week maintenance study (UC-2) for continued treatment over fifty-two weeks.


Controlled Release Drug Delivery Market Trends


  • Growing spending on R&D is driving the market growth


Market CAGR for controlled release drug delivery is being driven by the R&D. Constantly increasing R&D investment by pharmaceutical research companies concentrating on developing effective medicines for chronic and noncommunicable illnesses such as diabetes, cancer, and hypertension would most likely fuel market growth throughout the projection period. Taris, a biomedical R&D company, for example, has a controlled-release medication delivery system in their pipeline product TAR-200 (Gemcitabine), which is used to treat bladder cancer. Furthermore, Johnson & Johnson is scheduled to complete the acquisition of Taris Biomedical in 2020. One of the primary reasons for the purchase is its flagship investigational pharmaceutical, TAR-200.


The rising geriatric and pediatric population globally is driving market development, owing mostly to non-adherence to medication regimens, which is quite frequent among these age groups. Geriatric people have impaired physical, mental, and biological functioning, which impacts their medication usage. Furthermore, their bodies cannot endure excessive dosages and strong adverse effects of medications. As a result, the need for controlled-release medication delivery systems is predicted to rise in tandem with the patient population. Controlled-release drug administration provides for considerable dose and dosage frequency reductions, the prevention of aberrant fluctuations in plasma drug levels, improved effectiveness, improved patient compliance, and the achievement of the consistent pharmacological impact of the supplied medication. Control releases drug delivery systems, instead of standard delivery methods, produce a longer therapeutic impact by releasing medicine to the target location at a predetermined time and with predictable drug release kinetics. As a result of the additional benefits provided by the controlled release delivery system. Thus, driving the Controlled Release Drug Delivery market revenue.


Controlled Release Drug Delivery Market Segment Insights


Controlled Release Drug Delivery Route of administration Insights


The Controlled Release Drug Delivery market segmentation, based on the route of administration, includes the Wurster technique, coacervation, microencapsulation, implants, transdermal, and targeted delivery. The targeted delivery segment dominated the market, accounting for 35% of market revenue. Targeted delivery permits drugs to be placed away from regions that might induce drug toxicity while providing the desired site of action. It is a popular drug delivery method because it increases bioavailability and localizes the medicine, improving absorption, reducing changes in circulating drug levels, and lowering the risk of adverse effects.


Controlled Release Drug Delivery Release Mechanism Insights


The Controlled Release Drug Delivery market segmentation, based on release mechanism, includes polymer-based systems, micro reservoir partition controlled drug delivery systems, feedback-regulated drug delivery systems, activation-modulated drug delivery systems, and chemically activated. The feedback-regulated drug delivery systems segment dominated the market. Due to their usefulness in treating ailments, including diabetes. Furthermore, increased R&D initiatives to capitalize on the potential of feedback-regulated controlled ways of medication administration as countermeasures will promote market expansion. Furthermore, increased R&D initiatives to utilize the potential of feedback-regulated, controlled drug delivery systems as antidotes are likely to boost market expansion.


Controlled Release Drug Delivery Application Insights


The Controlled Release Drug Delivery market segmentation, based on Application, includes metered dose inhalers, injectable, infusion pumps, oral controlled-drug delivery systems, transdermal and ocular patches, and drug-eluting stents. The oral controlled-drug delivery systems generated the most income. Owing to its regular usage and availability. Metered dosage inhalers are another profitable market predicted to increase rapidly during the projection period. The rising frequency of respiratory illnesses and regular product and technology breakthroughs are projected to boost category growth in the long run.


Figure 1: Controlled Release Drug Delivery Market, by Application, 2022 & 2032 (USD Billion) 


Controlled Release Drug Delivery Market by Application


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Controlled Release Drug Delivery Regional Insights


By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Controlled Release Drug Delivery market area will dominate this market; government measures to support the development of controlled-release medication delivery and increasing R&D spending are projected to drive market expansion in the area. Furthermore, the presence of important market participants encourages using controlled-release medication delivery methods. The rising prevalence of chronic illnesses such as cancer, diabetes, and heart ailments is boosting market growth.


Thus, the major countries studied in the market report are The US, Canada, German, Japan, India, France, the UK, Italy, Spain, China, Australia, South Korea, and Brazil.


Figure 2: CONTROLLED RELEASE DRUG DELIVERY MARKET SHARE BY REGION 2022 (USD Billion) 


CONTROLLED RELEASE DRUG DELIVERY MARKET SHARE BY REGION


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Europe has the second-largest market share for Controlled Release Drug Delivery because of the region's increased R&D efforts and large pharmaceutical businesses. Furthermore, the German Controlled Drug Delivery market dominated, while the UK Controlled Drug Delivery market grew fastest in Europe.


From 2023 to 2032, the Asia-Pacific Controlled Release Drug Delivery Market will develop at the quickest CAGR. The region is getting international prominence as the pharmaceutical sector develops. Future growth of the market is predicted. Furthermore, China's Controlled Drug Delivery market had the highest market share, whereas India's Controlled Drug Delivery market was the Asia-Pacific region's fastest growing.


Controlled Release Drug Delivery Key Market Players & Competitive Insights


Leading market companies are extensively spending R&D on increasing their product lines, which will help the Controlled Release Drug Delivery market grow even more. Important market developments include new product releases, acquisitions and mergers, contractual agreements, greater investments, and collaboration with other organizations. The Controlled Release Drug Delivery industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.


Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide Controlled Release Drug Delivery industry to serve clients and expand the market sector. The Controlled Release Drug Delivery industry has provided some of the most important benefits recently. Ripple Therapies., AstraZeneca plc, and other major companies in the Controlled Release Drug Delivery market are aiming to enhance market demand by investing in research and development activities.


Ripple Therapies is a clinical-stage business that enhances ocular therapies through controlled, long-term drug delivery. Their executive team has managed small and big public and private firms through various stages of growth and funding techniques. They successfully sold Interface Biologics' surface modification business to Evonik in 2019 and formed Ripple Therapeutics in January 2020. Ripple's initial product, IBE-814 IVT, is a proprietary intravitreal Dexamethasone prodrug implant with a 6-9 month duration that targets diabetic macular edoema (DME) and retinal vein occlusion (RVO). The FDA has approved a 505(b)2 pathway for IBE-814 IVT, and a Phase 2 study is now underway. In February 2023, Ripple Therapeutics, a prominent ophthalmic continuous drug delivery company, and Hovione, a spray drying and particle engineering pioneer, have forged a strategic partnership to expand the use of Ripple's Epidel platform beyond ocular applications.


AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology corporation headquartered in Cambridge, England. Its product portfolio includes treatments for important cancer, cardiology, gastrointestinal, infection, neurology, respiratory, and inflammation disorders. It was engaged in the development of the Oxford-AstraZeneca COVID-19 vaccine. They are a worldwide pharmaceutical firm driven by research and focuses on patients. They are committed to altering the future of healthcare by using the power of science to benefit individuals, society, and the world. Their company is structured to meet their goal of pushing the limits of science to provide life-changing medicines through their innovative approach.Their R&D and commercial operations encourage faster decision-making and the introduction of novel medications across all their therapeutic areas. In December 2021, AstraZeneca is working on the next generation of medicine delivery technologies. The company's scientists are focused on removing obstacles between the most promising new medicine candidates and their targets in tissues and cells. Finally, these next-generation drug delivery technologies promise to translate the scientific progress that has led to the company's groundbreaking new modalities into therapeutic advantages for patients.


Key Companies in the Controlled Release Drug Delivery market include



  • Depomed, Inc. (US)

  • Coating Place, Inc.(US)

  • Corium International Inc.(US)

  • Alza Corporation (Johnson & Johnson)(US)

  • Pfizer Inc.(US)

  • SKY Pharmaceuticals Pvt. Ltd.(China)

  • AstraZeneca (US)

  • Biogen (US)

  • GlaxoSmithKline (UK)

  • Novartis (UK)

  • Allergan (‎Ireland)

  • Collegium Pharmaceutical (US).


Controlled Release Drug Delivery Industry Developments


March 2022:EUDRATEC SoluFlow is a novel microparticle technology developed by Evonik to improve the solubility of active medicinal components in oral medication formulations. Because more than 70% of novel small compounds are insoluble, EUDRATEC SoluFlow facilitates the discovery of new oral therapies across various disorders, including cancer, cardiovascular disease, infectious disease, and diabetes.


March 2022:Coloron introduced OptiClenz, a high-capacity, targeted, and repeatable cleaning system for tablet coating equipment.


Controlled Release Drug Delivery Market Segmentation


Controlled Release Drug Delivery Route Of Administration Outlook




  •  Wurster Technique




  • Coacervation




  • Micro Encapsulation




  • Implants




  • Transdermal




  • Targeted Delivery




Controlled Release Drug Delivery Release Mechanism Outlook




  • Polymer Based Systems




  • Micro Reservoir Partition Controlled Drug Delivery Systems




  • Feedback Regulated Drug Delivery Systems




  • Activation-modulated Drug Delivery Systems




  • Chemically Activated




Controlled Release Drug Delivery Application Outlook




  • Metered Dose Inhalers




  • Injectable




  • Transdermal




  • Ocular Patches




  • Infusion Pumps




  • Oral Controlled-drug delivery Systems




  • Drug Eluting Stents




Controlled Release Drug Delivery Regional Outlook




  • North America






  • US




  • Canada






  • Europe






  • Germany




  • France




  • UK




  • Italy




  • Spain




  • Rest of Europe






  • Asia-Pacific




    • China




    • Japan




    • India




    • Australia




    • South Korea




    • Australia




    • Rest of Asia-Pacific






  • Rest of the World




    • Middle East




    • Africa




    • Latin America





Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.